Compare The Coca-Cola Co K (KO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Merck & Co., Inc. — how do they compare? The Coca-Cola Co K trades at $88.05 (market cap $377.63B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: The Coca-Cola Co K and Merck & Co., Inc. are close in size by market cap, and The Coca-Cola Co K pays the higher dividend (2.42%). Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Merck & Co., Inc. for 98 Days on average.
| KO | MRK | |
|---|---|---|
Market Cap | $377.63B | $351.28B |
Volume | 14,894,568 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $156.43 |
52-Week Low | $66.80 | $82.49 |
Typical Hold Time | 154 Days | 98 Days |
Enterprise Value | $404.81B | $398.04B |
Dividend Yield | 2.42% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.77, up 2.27% today, with a bullish technical signal from moving averages and a strong fundamental profile. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $0.97 surpassing the $0.92 estimate. Revenue reached $47.94B in 2025, with net income margin improving to 28.56%. The company maintains a robust balance sheet with $14.57B in cash and a 64-year dividend growth streak, supported by steady cash flow from operations.
The outlook remains positive, supported by analyst consensus with a $95.75 price target and 60% buy ratings. Key opportunities include stable global demand and brand strength, while risks involve regional volume divergence and high valuation multiples. Long-term investors may find value in its defensive qualities and dividend reliability, though near-term volatility could persist amid macroeconomic uncertainties.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
